Selective T‑Cell Programming for Combinatorial CAR‑T/TCR‑T Solid Tumor Therapy

• Describing a combinatorial CAR‑T and TCR‑T strategy for solid tumors enabled by targeted viral engineering
• Paramyxovirus‑based pseudotyping will allow selective programming of distinct T‑cell subsets to generate complementary CAR‑T and TCR‑T products
• Improving tumor recognition and address antigen heterogeneity

Speakers:

Pradyot Dash

Associate Vice President & Head of Research & Development

Lentigen Technology, a subsidiary of Miltenyi Biotec